ReviewFrontiers in medicine2026
Ultra-widefield optical coherence tomography angiography in diabetic retinopathy: from retinal lesions to choroidal metrics.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic retinopathy (DR) continues to represent one of the principal etiologies of visual impairment among working-age populations, and the escalating global burden of diabetes mellitus suggests that this challenge will likely intensify in the coming decades. Conventional diagnostic modalities, most notably fluorescein angiography (FA), have long been employed as reference standards in clinical practice; nevertheless, these approaches are hampered by inherent drawbacks, including their invasive nature and the absence of depth-resolved structural information. The advent of optical coherence tomography angiography (OCTA) has provided a compelling non-invasive alternative capable of delivering depth-stratified vascular visualization. Subsequent technological refinements have yielded ultra-widefield (UWF) OCTA, which substantially extends the imaging field of view and affords detailed examination of the peripheral retinal vasculature that previously remained beyond the reach of conventional acquisition systems. The present review synthesizes current evidence regarding the clinical utility of UWF-OCTA in DR, with particular emphasis on its capacity to identify and characterize key retinal microvascular lesions, encompassing neovascularization (NV), non-perfusion areas (NPAs), microaneurysms (MAs), and intraretinal microvascular abnormalities (IRMAs). The vitreoretinal interface (VRI) slab for detecting NV, emerging choroidal metrics, and a comparison between UWF-OCTA and UWF-FA are also discussed. The evidence suggests that UWF-OCTA detects NV with high sensitivity and specificity, compares favorably to FA, and offers unique advantages, although limitations such as segmentation errors and a smaller field of view must be acknowledged. UWF-OCTA appears to be a promising non-invasive tool for DR diagnosis and monitoring, potentially complementing rather than completely replacing conventional angiography.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.